The purpose of this study is to compare virus response to GW433908/ritonavir (RTV) to viral response to nelfinavir (NFV) when used with abacavir (ABC)/lamivudine (3TC) in patients that have not taken antiretroviral (ART) drugs.
Patients are randomized to 1 of 2 treatment arms. One arm is treated with GW433908/RTV plus ABC and 3TC. The other is treated with NFV plus ABC and 3TC. Each group is treated for 48 weeks. The following are compared in the 2 arms: 1) magnitude and durability of antiviral response; 2) safety, tolerance, and antiviral response after 24 and 48 weeks of therapy; 3) time to treatment failure; 4) immunologic response; 5) occurrence of events related to metabolic abnormalities; and 6) development of viral resistance in a subset of patients following treatment. Also studied are: 1) steady-state plasma drug trough concentrations; 2) demographic, virologic, immunologic, pharmacologic, and adherence factors that may be associated with treatment outcome; 3) patient adherence to the drug regimens; 4) study medication utilization; and 5) resource utilization.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Enrollment
624
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Orange County Ctr for Special Immunology
Fountain Valley, California, United States
AIDS Healthcare Foundation
Los Angeles, California, United States
LAGLC
Los Angeles, California, United States
Kaiser Hospital
Sacramento, California, United States
Park Ctr for Health / Keith Vrhel
San Diego, California, United States
AIDS Research Alliance
West Hollywood, California, United States
Dupont Circle Physicians Group
Washington D.C., District of Columbia, United States
Infectious Disease Consultants
Altamonte Springs, Florida, United States
CRI of South Florida
Coral Gables, Florida, United States
Therafirst Med Ctr
Fort Lauderdale, Florida, United States
...and 27 more locations